On October 20, 2017, the U.S. Food an Drug Administration (FDA) licensed Shingrix ® to prevent shingles for adults age 50 years and older.
Here is the full prescribing information of Shingrix ®
There has been Zostavax® from Merck in the market.
This is the table of Shingrix ® vs Zostavax®
| Shingrix ® | Zostavax® | |
|---|---|---|
| indication | prevention of herpes zoster (shingles) in adults aged 50 years and older | prevention of herpes zoster (shingles) in individuals 50 years of age and older |
| vaccine | a non-live, subunit vaccine | a live attenuated virus vaccine |
| volume | 0.5 ml | 0.65 ml |
| Injection | for intramuscular injection only | for subcutaneous injection only |
| reconstitution | After reconstitution, administer immediately or store refrigerated between 2℃ and 8℃ (36℉ and 46℉) and use within 6 hours | Discard reconstituted vaccine if not used within 30 minutes. Do not freeze reconstituted vaccine |
| schedule | A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later | a single dose |
This is the link of one articles from CNN
http://www.cnn.com/2017/10/25/health/cdc-new-shingles-vaccine/index.html
